SAN DIEGO, CA USA (UroToday.com) - The emergence of several new agents that prolong survival for men with metastatic castrate resistant prostate cancer (mCRPC) has resulted in a fast-paced revolution of the advanced prostate cancer space.
Once faced with a dismal prognosis, now men with mCRPC have an increasing set of options that afford significantly longer survival. Importantly, data exist that show some of these therapies may also improve quality of life as well.
Abiraterone acetate (AA), a potent, selective androgen biosynthesis inhibitor, was prospectively evaluated as part of a large phase 3 trial (COU-AA-302: AA + prednisone vs. placebo + prednisone) in asymptomatic/mildly symptomatic, progressive, chemotherapy-naïve mCRPC patients. The authors of this study presented the updated results of the impact of AA on pain and functional status (using the BPI-SF and FACT-P questionnaires) with prior interim analysis demonstrating advantages for both. Encompassing over 1 000 patients and with a median follow-up of over 2 years, AA + P significantly prolonged the time to progression of pain and interference with activities of daily living. In combination with the previously reported overall and progression-free survival, the new findings of significant improvement in quality-of-life outcomes confirm the belief that AA is a beneficial therapeutic option for mCRPC patients prior to receiving chemotherapy.
Abstract Title: The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer: Results from an updated analysis
Presented by Neal Shore, Ethan Basch, Charles J. Ryan, Peter Mulders, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, and Charles Cleeland at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA
Reported for UroToday.com by Anthony T. Corcoran, MD